Xintela develops medical products in stem cell therapy and targeted cancer therapy based on the Company's cell surface marker integrin α10β1 which is found on mesenchymal stem cells and on certain aggressive cancer cells. The stem cell marker is used to select and quality-assure the patent-protected stem cell product XSTEM®, which is in clinical development for treatment of knee osteoarthritis and difficult-to-heal leg ulcers. The company produces XSTEM for the clinical studies in its GMP-approved manufacturing facility. In cancer therapy, which is run by the wholly owned subsidiary Targinta AB, therapeutic antibodies, targeting integrin α10β1 (First-in-Class) are being developed for the treatment of triple-negative breast cancer and the brain tumor glioblastoma.
View Top Employees from Xintela ABWebsite | http://www.xintela.se |
Revenue | $6 million |
Employees | 23 (19 on RocketReach) |
Founded | 2009 |
Address | 1 Scheeletorget, Lund, Skane 223 81, SE |
Phone | +46 46 275 65 00 |
Technologies |
JavaScript,
HTML,
Twitter
+11 more
(view full list)
|
Industry | Biotechnology, Biotechnology Research, Business Services General, Alternative Medicine, Alpha 10 Marker technology, Business Services, Health Care, Drug Discovery, Regenerative Medicine, Cancer, Science and Engineering, Medical |
Web Rank | 19 Million |
Competitors | Cellerant Therapeutics, MIS.CARBONART, SanBio, TCR² Therapeutics Inc., ViaCyte |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 54171 Companies, NAICS Code 5417 Companies, NAICS Code 541713 Companies, NAICS Code 541 Companies, NAICS Code 54 Companies |
Looking for a particular Xintela AB employee's phone or email?
The Xintela AB annual revenue was $6 million in 2024.
Camilla Wennersten is the Director Clinical Development of Xintela AB.
19 people are employed at Xintela AB.
Xintela AB is based in Lund, Skane.
The NAICS codes for Xintela AB are [54171, 5417, 541713, 541, 54].
The SIC codes for Xintela AB are [873, 87].